The vagus nerve slows the heart. That’s its primary cardiac function — releasing acetylcholine at the sinoatrial (SA) node to reduce heart rate and at the atrioventricular (AV) node to slow conduction. So when you electrically stimulate the vagus nerve, bradycardia (an abnormally slow heart rate, below 60 bpm) is a predictable physiological consequence, not a treatment target. VNS-induced bradycardia is a well-documented side effect of vagus nerve stimulation therapy, particularly during device implantation and lead testing. Understanding this risk — how common it is, when it’s dangerous, and how it’s managed — matters for anyone considering or already using a VNS device.
Why VNS Slows the Heart
The mechanism is straightforward. The vagus nerve is the primary parasympathetic input to the heart. The right vagus predominantly innervates the SA node (the heart’s natural pacemaker), and stimulating it reduces the rate at which the SA node fires. The left vagus predominantly innervates the AV node, slowing conduction from the atria to the ventricles. Most implantable VNS devices (used for epilepsy and depression) are placed on the left cervical vagus specifically to reduce cardiac effects — left-sided stimulation primarily slows AV conduction rather than SA node firing, producing less pronounced bradycardia than right-sided stimulation would.
When the VNS device delivers its electrical pulse (typically 30 seconds on, 5 minutes off), the stimulation activates vagal efferent fibres heading to the heart. At therapeutic stimulation parameters (1.0-2.5 mA, 20-30 Hz, 250-500 microsecond pulse width), this causes a transient, mild heart rate reduction in most patients — usually 5-15 bpm below baseline during the on cycle, returning to normal during the off cycle. This cyclic heart rate fluctuation is clinically insignificant for most people and is not the same as pathological bradycardia.
When VNS-Induced Bradycardia Becomes Dangerous
The most significant bradycardia risk occurs during intraoperative lead testing — the moment during VNS implantation surgery when the surgeon first tests the electrode to confirm proper placement. Several case reports have documented asystole (complete cessation of heartbeat) lasting 10-30 seconds during initial lead testing, presumably because the first stimulation pulse activates a disproportionate number of cardiac vagal fibres before the nerve accommodates. The estimated incidence of clinically significant intraoperative bradycardia or asystole during VNS implantation is roughly 0.1-1%, based on case series and post-market surveillance data.
Management is straightforward: continuous cardiac monitoring during implantation allows immediate detection. If asystole occurs, the stimulation is stopped (the surgeon deactivates the device), and normal heart rhythm typically resumes spontaneously within seconds. Atropine (a vagolytic drug that blocks acetylcholine at the heart) is kept available as a pharmacological rescue. In rare cases where asystole is prolonged, standard advanced cardiac life support protocols apply. Because of this risk, VNS implantation is always performed with full cardiac monitoring and resuscitation equipment immediately available.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- HRV biofeedback
- Polyvagal-informed therapy
- Somatic therapy
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Chronic VNS and Heart Rate Effects
In long-term VNS therapy, clinically significant bradycardia is uncommon. The vagus nerve exhibits accommodation — over time, the nerve fibres become less responsive to the same stimulus intensity, and the cardiac effects diminish. Most patients on chronic VNS show a small, cyclical heart rate variation (a mild dip during the on cycle) that they don’t feel and that has no clinical significance.
However, certain patient populations are at higher risk for clinically significant bradycardia during chronic VNS therapy. These include patients already taking heart rate-lowering medications (beta-blockers, calcium channel blockers, digoxin, or ivabradine), patients with pre-existing conduction abnormalities (sick sinus syndrome, second- or third-degree AV block), and patients with baseline resting heart rates near or below 60 bpm. For these patients, careful titration of VNS parameters (slower current ramp-up, lower maximum current, wider off-period) can reduce the bradycardia risk. In some cases, cardiac monitoring with Holter or implantable loop recorder during VNS initiation is warranted.
Late-Onset VNS Bradycardia
A rarer but documented phenomenon is late-onset bradycardia — clinically significant heart rate slowing that develops months to years after VNS implantation, sometimes after a parameter increase. The mechanism is not fully understood, but may involve changes in vagal fibre recruitment as the electrode-nerve interface evolves (scar tissue formation can change current distribution across the nerve cross-section, potentially recruiting more cardiac fibres over time). Case reports have described symptomatic bradycardia (dizziness, pre-syncope, fatigue) requiring VNS parameter reduction or device deactivation. This is why patients on VNS therapy should report any new symptoms of lightheadedness, exercise intolerance, or unexplained fatigue to their neurologist.
VNS and Pre-Existing Cardiac Conditions
Patients with epilepsy have a higher-than-average risk of sudden unexpected death in epilepsy (SUDEP), which is often attributed to postictal cardiac or respiratory dysfunction — both involving the vagus nerve. The question of whether VNS increases or decreases SUDEP risk has been debated. Current evidence suggests that VNS does not increase SUDEP risk and may modestly reduce it (possibly by reducing seizure frequency and severity). However, VNS is generally contraindicated in patients with pre-existing bradyarrhythmias that would be worsened by additional vagal stimulation.
For patients with cardiac conditions who need VNS, collaboration between neurology and cardiology is essential. Some patients have both a VNS device and a cardiac pacemaker — the pacemaker provides a safety net by pacing the heart if VNS-induced bradycardia drops below a set threshold. Device-device interactions (electromagnetic interference between VNS and cardiac pacemaker/defibrillator) are manageable with modern devices but require careful programming and monitoring.
Differentiating VNS-Induced Bradycardia from Vagally Mediated Bradycardia
It’s important to distinguish VNS-induced bradycardia (caused by a stimulation device) from the broader category of vagally mediated bradycardia, which occurs naturally. Resting bradycardia in athletes (HR 40-60 bpm) is a normal adaptation driven by high vagal tone. Vasovagal syncope — fainting triggered by standing, pain, emotional stress, or blood draws — involves a sudden surge in vagal output that drops heart rate and blood pressure. Situational bradycardia occurs during Valsalva manoeuvre, vomiting, defecation, or the diving reflex. None of these are caused by VNS devices, and they require different clinical approaches. Post 3588 on this site covers vagal heart conditions broadly, and post 3664 covers vasovagal syncope specifically.
Bottom Line for VNS Patients
If you have a VNS device: the cardiac risk is real but manageable. Intraoperative asystole is the highest-risk moment and is handled by your surgical team. Chronic bradycardia is uncommon, usually mild, and responsive to parameter adjustment. Report any new symptoms of lightheadedness, fatigue, or exercise intolerance. If you take heart rate-lowering medications, make sure your neurologist and cardiologist are communicating about your VNS settings. And if you’re being evaluated for VNS, a baseline cardiac assessment (ECG, resting heart rate, review of cardiac medications) should be part of the pre-operative workup.
Want to understand the full relationship between your vagus nerve and your heart? Get the Vagus Nerve & Me eBook for evidence-based coverage of cardiac vagal function, from HRV to heart rhythm disorders.
